Diagnostics firm PixCell acquired by Soulbrain
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that Soulbrain Holdings has acquired all controlling PixCell shares, as well as investing in the company, making Soulbrain the majority shareholder of PixCell Medical.
The acquisition of PixCell aligns with Soulbrain’s recent strategic transition into the healthcare and in-vitro diagnostics space.
Soulbrain, a semiconductor specialist, recently chose the bio-healthcare industry as an engine for growth and has already made several acquisitions and investments. The company identified PixCell as a good fit for its strategy of entering the diagnostics and point-of-care testing space, with a purpose of distributing specialised diagnostic reagents and miniaturised medical devices.
Dr. Nam Huh, head of bio-healthcare division and vice president at Soulbrain, said: “We identified PixCell Medical as a company proven to have disruptive technology in the healthcare field and are proud to have them join the Soulbrain family. Striving to acquire technologies that will serve as the foundation of future industry development is our focus, and we have diversified our business portfolio to include distribution of specialised diagnostic reagents and miniaturised medical devices focused on point-of-care. Providing higher added value and satisfaction to our customers is our top priority, and PixCell is a great addition to our growing family of competitive life science daughter companies.”
PixCell Medical’s flagship product, HemoScreen, is a point-of-care blood testing platform that can conduct blood cell analysis within five minutes by applying AI-driven novel microfluidic and lab-on-a-cartridge technology. FDA-cleared, CE-marked and TGA-approved, the HemoScreen conducts five-part differential complete blood count (CBC) tests, producing results equivalent to laboratory analysers in significantly less time. By applying a novel, patented microfluidics method called Viscoelastic Focusing to conduct the cell analysis, PixCell has miniaturised traditionally large and complex machinery.
Dr. Avishay Bransky, co-founder and CEO of PixCell Medical, said: “This deal is crucial for PixCell’s global expansion and commercialisation of the HemoScreen. We believe Soulbrain will be an excellent strategic partner, helping accelerate our growth while continuing to provide accessible and accurate haematological test results on a global scale. Our goal is to deliver reliable, simple and affordable diagnostic information to those in need – be it patients with chronic illnesses or people living in remote areas with lack of access to healthcare. Partnering with Soulbrain is an important milestone for us in achieving that goal.”